Company Overview of AC Immune SA
AC Immune SA, a biopharmaceutical company, develops vaccines, antibodies, and small molecules for conformational diseases and cancer. The company develops active and passive immunotherapies against Alzheimer's disease using its molecular technology platform. It offers ACI-24, an Alzheimer's disease vaccine, which is designed to act as an active vaccine stimulating the patient's immune system to produce beta-sheet conformation-specific antibodies that prevent plaque deposition or enhance clearance of plaques; ACI-01-Ab7, a monoclonal antibody and passive immunotherapy; and Morphomers and ACI-91, the small molecules products. AC Immune SA was founded in 2003 and is based in Lausanne, Switzerla...
PSE Building B - EPFL
Founded in 2003
Key Executives for AC Immune SA
Co-Founder and Chief Executive Officer
Co-Founder and Member of the Scientific Advisory Board
Compensation as of Fiscal Year 2014.
AC Immune SA Key Developments
AC Immune SA and Piramal Imaging Announce Out-Licensing Agreement for the Development of Tau Protein Diagnostics in Alzheimer's Disease
May 12 14
AC Immune SA and Piramal Imaging entered into an exclusive worldwide license agreement for the research, development and commercialization of AC Immune's Tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of Alzheimer's disease (AD) and potential Tau-related disorders. The formation of Tau tangles in the human brain is recognized as one of two major hallmarks of Alzheimer's disease pathology, with the other being beta-amyloid plaques. The development of the Tau tangle pathology appears to correlate well with cognitive decline, making it a potential strong target for diagnostic approaches. The availability of a Tau-PET tracer for imaging Tau tangles in the brain of patients would represent important progress towards relevant diagnostic endpoints and could be of significant value in guiding clinical trials for disease modifying AD therapeutics. Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and is eligible for significant milestone payments on products achieving development goals in AD and other Tauopathies. Additionally, AC Immune is entitled to receive tiered royalties on net sales of products resulting from the partnership. AC Immune will work in collaboration with Piramal Imaging to efficiently advance several lead candidates through late pre-clinical radio-pharmacology development. Piramal Imaging will have global rights for clinical development, manufacturing and commercialization of a Tau-PET Tracer resulting from the collaboration. Financial details were not disclosed. The agreement between the two companies is based on a long-term relationship in which AC Immune has used Piramal Imaging's beta-amyloid PET Tracer Neuraceq(TM) for imaging beta-amyloid plaques in the brain of patients undergoing Phase I/IIa clinical testing of AC Immune's Alzheimer's vaccine ACI-24. Neuraceq(TM) received marketing authorization from the FDA on March 19, 2014 for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline. Safety and effectiveness of Neuraceq(TM) have not been established for monitoring responses to therapies. Neuraceq(TM) received similar approval by the EC four weeks earlier.
AC Immune SA Presents at BioEquity Europe 2014, May-21-2014 04:00 PM
Mar 14 14
AC Immune SA Presents at BioEquity Europe 2014, May-21-2014 04:00 PM. Venue: Hilton Amsterdam Hotel, Amsterdam, Netherlands.
Molecular and AC Immune Reportedly Mulls IPO
Mar 13 14
Molecular Partners AG and AC Immune are reportedly seeking IPO. In a statement, AC Immune said an IPO was only one option. Molecular Partners was not immediately available to comment.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 9, 2014
Most Searched Private Companies
Sponsored Financial Commentaries